Cardioprotective Effects of Aloysia polystachya Essential Oil on a Rat Model with Multiple Cardiovascular Risk Factors
This study aimed to investigate the protective effects of the essential oil extracted from the leaves of A. polystachya in a rat model that simulates multiple cardiovascular risk factors. We evaluate the acute toxicity, as well as the cardioprotective effects, by giving different doses of A. polystachya essential oil (1.47 mg/kg, 4.40 mg/kg, and 13.20 mg/kg) over a period of 42 days. The control group was treated with rosuvastatin (5 mg/kg). At the end of the treatments, the renal function, electrocardiography, blood pressure, vascular reactivity, serum biochemical profile, and organ histopathology were evaluated...
Source: Planta Medica - April 17, 2024 Category: Drugs & Pharmacology Authors: Moreno, Karyne Garcia Tafarelo Marques, Aline Aparecida Macedo da Silva, Gabriela Pereira Bertoncelo, Luana Ale Pessoal, Luciane Barbosa Gon çalves, Larissa Dantas dos Santos, Ariany Carvalho Souza, Roosevelt Isa ías Carvalho Silva, Denise Brentan Gaspa Tags: Original Papers Source Type: research
Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk
J Clin Med. 2024 Mar 25;13(7):1894. doi: 10.3390/jcm13071894.ABSTRACTVascular diseases are the leading cause of death in Spain. Hypercholesterolemia is not only a cardiovascular risk factor, but also underlies the etiopathogenesis of atherosclerosis. Therefore, reducing LDL cholesterol (LDL-C) to the goals recommended by clinical practice guidelines, is essential to decrease the risk of vascular complications. Despite this, current LDL-C control is scarce, even in subjects with high and very high risk. This is mainly due to an insufficient intensification of lipid-lowering treatment. In this context, it is essential to pre...
Source: Atherosclerosis - April 13, 2024 Category: Cardiology Authors: Jose Mar ía Mostaza Carlos Escobar Source Type: research
The maximum dose of atorvastatin and simvastatin as well as rosuvastatin should be restricted in East Asians
Hong Kong Med J. 2024 Apr 12. doi: 10.12809/hkmj2311348. Online ahead of print.NO ABSTRACTPMID:38605565 | DOI:10.12809/hkmj2311348 (Source: Hong Kong Med J)
Source: Hong Kong Med J - April 12, 2024 Category: General Medicine Authors: B Tomlinson E Chow Source Type: research
The maximum dose of atorvastatin and simvastatin as well as rosuvastatin should be restricted in East Asians
Hong Kong Med J. 2024 Apr 12. doi: 10.12809/hkmj2311348. Online ahead of print.NO ABSTRACTPMID:38605565 | DOI:10.12809/hkmj2311348 (Source: Hong Kong Medical Journal)
Source: Hong Kong Medical Journal - April 12, 2024 Category: General Medicine Authors: B Tomlinson E Chow Source Type: research
The maximum dose of atorvastatin and simvastatin as well as rosuvastatin should be restricted in East Asians
Hong Kong Med J. 2024 Apr 12. doi: 10.12809/hkmj2311348. Online ahead of print.NO ABSTRACTPMID:38605565 | DOI:10.12809/hkmj2311348 (Source: Hong Kong Med J)
Source: Hong Kong Med J - April 12, 2024 Category: General Medicine Authors: B Tomlinson E Chow Source Type: research
The maximum dose of atorvastatin and simvastatin as well as rosuvastatin should be restricted in East Asians
Hong Kong Med J. 2024 Apr 12. doi: 10.12809/hkmj2311348. Online ahead of print.NO ABSTRACTPMID:38605565 | DOI:10.12809/hkmj2311348 (Source: Hong Kong Medical Journal)
Source: Hong Kong Medical Journal - April 12, 2024 Category: General Medicine Authors: B Tomlinson E Chow Source Type: research
The maximum dose of atorvastatin and simvastatin as well as rosuvastatin should be restricted in East Asians
Hong Kong Med J. 2024 Apr 12. doi: 10.12809/hkmj2311348. Online ahead of print.NO ABSTRACTPMID:38605565 | DOI:10.12809/hkmj2311348 (Source: Hong Kong Med J)
Source: Hong Kong Med J - April 12, 2024 Category: General Medicine Authors: B Tomlinson E Chow Source Type: research
The maximum dose of atorvastatin and simvastatin as well as rosuvastatin should be restricted in East Asians
Hong Kong Med J. 2024 Apr 12. doi: 10.12809/hkmj2311348. Online ahead of print.NO ABSTRACTPMID:38605565 | DOI:10.12809/hkmj2311348 (Source: Hong Kong Medical Journal)
Source: Hong Kong Medical Journal - April 12, 2024 Category: General Medicine Authors: B Tomlinson E Chow Source Type: research
Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase
Biochem Biophys Res Commun. 2024 Mar 28;710:149841. doi: 10.1016/j.bbrc.2024.149841. Online ahead of print.ABSTRACTProstate cancer is the most prevalent malignancy in men. While diagnostic and therapeutic interventions have substantially improved in recent years, disease relapse, treatment resistance, and metastasis remain significant contributors to prostate cancer-related mortality. Therefore, novel therapeutic approaches are needed. Statins are inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway which plays an essential role in cholesterol homeostasis. N...
Source: Biochemical and Biophysical Research communications - April 8, 2024 Category: Biochemistry Authors: Andy G öbel Sophie P ählig Anja Motz Dorit Breining Sofia Traikov Lorenz C Hofbauer Tilman D Rachner Source Type: research
Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase
Biochem Biophys Res Commun. 2024 Mar 28;710:149841. doi: 10.1016/j.bbrc.2024.149841. Online ahead of print.ABSTRACTProstate cancer is the most prevalent malignancy in men. While diagnostic and therapeutic interventions have substantially improved in recent years, disease relapse, treatment resistance, and metastasis remain significant contributors to prostate cancer-related mortality. Therefore, novel therapeutic approaches are needed. Statins are inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway which plays an essential role in cholesterol homeostasis. N...
Source: Cell Research - April 8, 2024 Category: Cytology Authors: Andy G öbel Sophie P ählig Anja Motz Dorit Breining Sofia Traikov Lorenz C Hofbauer Tilman D Rachner Source Type: research
Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase
Biochem Biophys Res Commun. 2024 Mar 28;710:149841. doi: 10.1016/j.bbrc.2024.149841. Online ahead of print.ABSTRACTProstate cancer is the most prevalent malignancy in men. While diagnostic and therapeutic interventions have substantially improved in recent years, disease relapse, treatment resistance, and metastasis remain significant contributors to prostate cancer-related mortality. Therefore, novel therapeutic approaches are needed. Statins are inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway which plays an essential role in cholesterol homeostasis. N...
Source: Biochemical and Biophysical Research communications - April 8, 2024 Category: Biochemistry Authors: Andy G öbel Sophie P ählig Anja Motz Dorit Breining Sofia Traikov Lorenz C Hofbauer Tilman D Rachner Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Atherosclerosis)
Source: Atherosclerosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
